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Abstract
Background:  Human Papillomaviruses (HPV) are double-stranded DNA viruses, considered to be the primary
etiological agents in cervical intraepithelial neoplasias and cancers. Approximately 15–20 of the 40 mucosal HPVs confer
a high-risk of progression of lesions to invasive cancer. In this study, we investigated the prevalence of sexually
transmitted HPVs in Human Immunodeficiency Virus (HIV) positive and negative patients in Zambia, Africa. The rate of
high-risk HPV genotypes worldwide varies within each country. Thus, we sought to investigate the rates of HPV infection
in sub-Saharan Africa and the potential role of HIV in affecting the HPV genotype distribution.
Methods: This retrospective cross-sectional study reports findings on the association and effects of HIV on HPV
infections in an existing cohort of patients at University Teaching Hospital (UTH) Lusaka, Zambia. The objective of this
study was to assess HPV prevalence, genotype distribution and to identify co-factors that influence HPV infection.
Polymerase chain reaction (PCR) with two standard consensus primer sets (CpI/II and GP5+/6+) was used to test for
the presence of HPV DNA. Primers specific for β-actin were used to monitor DNA quality. Vaginal lavage samples,
collected between 1998-1999 from a total of 70 women, were part of a larger cohort that was also analyzed for HIV and
human herpesvirus infection. Seventy of the samples yielded usable DNA. HIV status was determined by two rapid assays,
Capillus and Determine. The incidence of HIV and HPV infections and HPV genotype distributions were calculated and
statistical significance was determined by Chi-Squared test.
Results: We determined that most common HPV genotypes detected among these Zambian patients were types 16 and
18 (21.6% each), which is approximately three-fold greater than the rates for HPV16, and ten-fold greater than the rates
for HPV18 in the United States. The worldwide prevalence of HPV16 is approximately 14% and HPV18 is 5%. The overall
ratio of high-risk (HR) to low-risk (LR) HPVs in the patient cohort was 69% and 31% respectively; essentially identical to
that for the HR and LR distributions worldwide. However, we discovered that HIV positive patients were two-times as
likely to have an HR HPV as HIV negative individuals, while the distribution of LR HPVs was unaffected by HIV status.
Interestingly, we observed a nine-fold increase in HPV18 infection frequency in HIV positive versus HIV negative
individuals.
Conclusion: The rate of oncogenic HPVs (type 16 and 18) in Zambia was much higher than in the U.S., potentially
providing an explanation for the high-rates of cervical cancer in Zambia. Surprisingly, we discovered a strong association
between positive HIV status and the prevalence of HR HPVs, and specifically HPV18.
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Background
Human papillomavirus (HPV) is the primary etiological
agent causing 95% of cervical cancers. Over 200 HPV
types have been recognized and approximately 40 have
been shown to infect the genital tract [1,2]. Even though
genital HPV infection is one of the most common sexually
transmitted infections, only about 10% of people in the
U.S. have active HPV infections, with 4% having cytolog-
ical abnormalities and 1% showing evidence of genital
warts [3]. Epidemiological evidence gathered over the last
decade has designated 15–20 of the 40 mucoso-tropic
HPV types (HPV16, 18, 45, 31, 33, 58, 52, 35, 59, 56, 6,
51, 68, 39, 82, 73, and 70) as associated with a high risk
of progression to cervical cancer [1,2,4,5]. In addition,
there is recent speculation that HPV26, 53, and 66 should
also be considered high-risk strains [6-10], however, there
is still some disagreement about these designations. The
frequency of individual high-risk HPV types worldwide
has been shown to vary in respect to major global regions
such as Asia, Europe, North America, South America, and
Sub-Saharan Africa [4,5,11]. Despite frequency variation,
HPV16 infection has been shown to be exceedingly more
prevalent than any other high-risk HPV type in these glo-
bal regions. An exception to this trend has been observed
in Human Immunodeficiency Virus (HIV) positive popu-
lations where HPV16 has shown to be frequent, but not as
predominating as seen in most HIV negative populations
[12-16]. Recent studies on the correlation between HIV
and HPV infections indicate higher frequencies of high-
risk HPV types in HIV positive individuals as opposed to
the usual genotypic frequencies observed in HIV negative
populations.
Impaired cell-mediated immunity could be a likely expla-
nation for the advancement of HR HPVs in HIV positive
individuals. Several studies have shown a strong and con-
sistent association between human immunodeficiency
virus (HIV) and HPV co-infection and the development of
CIN and genital cancer [17-20]. There is evidence to show
that HIV positive women have a significantly higher rate
of CIN than their counterparts and are more likely to
progress to invasive carcinoma than HIV negative women
[21-23]. A recent study in Brazil has shown that a very
high proportion of HIV infected women are infected with
HPV and they often carry multiple HPV genotypes (15).
Methods
Participants and ethical precautions
This study reports findings from a cross-sectional analysis
of data from a cohort study on the association and effects
of HIV on HPV infections. All human subjects protocols
were approved by safety committees at the University of
Zambia and UNL in accordance with the Helsinki Decla-
ration. Participation by patients was entirely voluntary
and written patient consent was required for inclusion in
the study. The objective of this study was to assess effects
of HIV status on HPV prevalence, distribution of HPV gen-
otypes and assess associated risk factors involved with
HPV infection.
Zambia is part of an ongoing study site to follow HIV and
secondary viral infections in women of child-bearing age
at the UTH, the largest tertiary care institution in the coun-
try and the main referral center for Lusaka, the capital of
the country. Between September 1998 and October 1999,
female patients were approached for enrollment in the
study. Those who were clinically diagnosed with KS,
AIDS, TB, malaria, cancer or had any other adverse health
conditions, were not eligible to participate in the study. In
addition, residence in the metropolitan area of Lusaka
was required. Disease histories as well as physical exami-
nations were carried out to rule out any clinical symptoms
or visible signs for these conditions. All of the participants
had normal pap smears. A total of 70 vaginal lavage sam-
ples obtained from these women were analyzed,
Demographic data collection
All study participants who signed informed consent and
were evaluated by study clinicians. A set of pre-tested,
standardized questionnaires was used to gather data [24].
Of 80 questionnaires 10 were not completed in full and
were thus excluded from any socio-demographic analysis,
leaving complete data for 70 patients. All personal identi-
fiers were removed from samples to ensure patient confi-
dentiality. With patients' permission, medical history was
retrospectively retrieved from hospital medical records.
A total of 154 variables were identified and assessed in
this study. Data were collected regarding seven areas of
interest that included: (i) socio-demographics (age, edu-
cation, household income, marital status, occupation,
religion, and tribal identity); (ii) current medical standing
(weight, diagnosis of tuberculosis, and diagnosis of spe-
cific ulcerative and non-ulcerative STDs); (iii)  medical
history (history of blood transfusion, hypertension, drug
abuse, and use of antibiotics in past 12 months); (iv)
reproductive and obstetric history (number and outcomes
of pregnancies, use of family planning and birth control
methods including condoms); (v)  history of sexually
transmitted disease (histories of STDs, genital ulceration,
vaginal discharge, and cancer including cervical dyspla-
sia);  (vi)  sexual behavior history (age at first sexual
encounter, steady partner in past 3 years, new partners in
past 3 years, sex with partner with penile lesion, sex under
influence of alcohol, anal intercourse, being raped, prac-
tice of dry sex, and use of herbs vaginally; and (vii) labo-
ratory test results (pap smears, results of serological
testing for HHV-8, HIV-1, and syphilis).BMC Infectious Diseases 2007, 7:77 http://www.biomedcentral.com/1471-2334/7/77
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Sample collection
Blood specimens were collected via venipuncture into
acid-citrate-dextrose tubes and processed using centrifuga-
tion at the on-site study laboratory within 6 hr of being
drawn. The separated plasma was frozen at -20°C and the
blood cells at -80°C. Vaginal lavage samples and pap
smears were collected from all patients. Pap smears were
examined and classified according to the pap classifica-
tion protocol; pap I (normal), pap II (inflammation), pap
III (dysplasia), pap IV (carcinoma in situ), and Pap V (car-
cinoma). For the purposes of the current study, only sam-
ples from patients with normal pap smears were analyzed
for HPV. Vaginal lavage specimens were stored at -20°C.
All specimens were then shipped to the Nebraska Center
for Virology at the University of Nebraska-Lincoln (UNL)
for sera and lavage testing.
DNA isolation
Seventy cervico-vaginal lavage samples stored at -80°C
were thawed, centrifuged and supernatant discarded.
DNA was extracted using the Qiagen Tissue extraction kit
(Dneasy). The DNA concentration was determined by UV
spectrophotometer at 260 nm.
PCR and gel electrophoresis
The quality of DNA isolation of was tested by β-actin
amplification in all the 70 samples. HPV detection was
carried out in all 70 samples using two sets of primers:
GP5+(5'-TTTGTTACTGTGGTAGATACTAC-3'), GP6+ (5'-
GAAAAATAAACTGTAAATCATATTC-3') and CPI (5'-
TTATCWTATGCCCAYTGTACCAT-3'), CPII (5'-ATGT-
TAATWSAGCCWCCAAAATT-3') [25]. The conditions
used for both primer sets were as follows: 1.5 mM MgCl2,
100  µM deoxynucleotide triphosphate (dNTP), 100
pmoles of each primer and 2.5 U of Taq polymerase (Inv-
itrogen). A total reaction of 50 µl containing 1 µl template
DNA was amplified according to the following PCR pro-
gram of 94°C for 5 min followed by 40 cycles (95°C for
30s, 44°C for 1 min, 72°C for 90s) and 72°C for 10
min[25]. HPV16 plasmid DNA (pEF399) was used as pos-
itive control and water was used as a negative control. Dis-
cordant and negative samples were repeated using 1 µl, or
5 µl of template DNA, as necessary. Twenty-five µl of the
PCR reaction was applied to 2% agarose gel and electro-
phoresed at 100 V for 105 min and stained in ethidium
bromide. Positive bands were excised from the gel and the
QIAquick Gel Extraction Kit protocol was used to purify
the DNA (QIAGEN Inc. CA, USA). The pGEM-T vector sys-
tem (Promega Corporation. WI, USA) was used to clone 3
µl of PCR product in a 10 µl reaction using the manufac-
turer's protocol. The reactions were incubated at 4°C over-
night for maximum number of transformants. LB Media/
ampicillin/isopropyl-beta-D-thiogalactopyranoside
(IPTG)/5-bromo-4-chloro-3-indolyl-beta-D-galactopyra-
noside (X-GAL) plates were prepared (10 µl (200 mg/ml)
of IPTG, 40 µl (20 mg/ml) of X-GAL). Locally prepared E.
coli  competent cells (75 µl/plate) were used and were
incubated at 37°C overnight. At least three white colonies
were selected from each plate and cultured in 5 ml LB/
ampicillin (100 µg/ml) broth overnight at 37°C. Purifica-
tion of plasmid DNA was carried out using QIAprep Spin
Miniprep Kit (QIAGEN Inc. CA, USA), according to the
protocol. Plasmid DNA was stored at 4°C for future use.
HPV genotype identification
The sequence data from both CPI/CPII and GP5+/GP6+
PCR products was used to determine the HPV genotypes
by conducting a BLAST search analysis against the NCBI
database of viral DNAs. The genotype for each sample was
determined with at least 100 nucleotides of DNA
sequence.
HIV tests
Plasma was tested in the study laboratory designated for
HIV diagnosis blinded from HPV testing and diagnosis.
HIV-1 serological status was established using two rapid
assays, Capillus (Trinity Biotech, Bray Co., Wicklow, Ire-
land) and Determine (Abbott Laboratories, Abbott Park,
IL), following manufacturers' suggested procedures.
Plasma that tested positive by Capillus assay was con-
firmed by a Determine assay and vice versa. We were
blinded as to the HIV status of all of the patients until after
all HPV tests were completed.
Statistical analysis
Classification of HPV types into high and low-risk catego-
ries were assessed according to previous descriptions.
High-risk HPV types included: 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68, 73, 82, and 83 [6,9,26]. The pri-
mary goals of statistical analysis were to record the disper-
sal of HR and LR HPVs, characterize prevalence of HPV
genotypes associated with this Zambian group, infer the
presence, or lack of a relationship between HIV and HPV
infections, and assess effects of HIV infection on distribu-
tion of HPV genotypes and perhaps the rate of dual HPV
infections.
Presence of any HPV (Table 1) for a given socio-demo-
graphic characteristic did not account for multiple infec-
tions. Multiple infections were treated as presence of HPV
and participants were not counted multiply for presence
of more than one HPV. HR and LR HPV prevalence (Table
1) for soci-demographic characteristics were calculated as
a function of HR or LR infections for total number of par-
ticipants. Multiply infected participants thus accounted
for more than one HPV infection but only one participant.
Chi-Squared derived P values were also given in Table 1 to
represent the significance of the statistical variation. To
ensure that statistically significant differences could beBMC Infectious Diseases 2007, 7:77 http://www.biomedcentral.com/1471-2334/7/77
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detected with the sample size, a power analysis was per-
formed using the G*Power program for Macintosh.
Results
Demographic characteristics
Seventy patients from ages 15 to 38 years old, with normal
cytology and verified HPV test results, were utilized for
analysis. Among the 70 patients, 8 tested positive for the
presence of multiple HPVs. HPV data was analyzed in the
following tables and figures as infectious events, resulting
in patients multiply infected being counted more than
once.
To ensure that differences between conditions could be
distinguished, a power analysis was performed using a
sample size of 70 with an effect size of 0.5 and alpha set
to 0.05. The resulting power calculated was 0.99. Given a
sample size of 70, a Chi-Squared test at an alpha of 0.5
will have the power to detect a difference of at least 3.8 in
the samples.
Socio-demographic characteristics of the study group are
represented in Table 1. Median age of study participants
was 22 years of age with a standard deviation of 5.2. Study
participants median age of first sexual intercourse (sexual
debut) was 17 years of age (standard deviation of 2.3).
Zambia has three predominant tribal identities, Bemba,
Nyanga, and Tonga. These majority identities were repre-
sented in the study cohort. The majority Bemba tribe was
represented in the study by 37.9% of the participants,
whereas, Nyanga and Tonga tribes were represented in the
study group at 36.4% and 15.1%. Other minority tribes,
Kaonde, Lozi, and Luvale, were represented in the study at
significantly lower numbers. An overwhelming majority
of study participants, over 90%, reported themselves as
married (formal or common-law marriage). Approxi-
mately 35% attended or completed only primary educa-
tion (1–7 years), whereas 25% had secondary education
(8–12 years) and 6.2% had received some form of tertiary
education.
Behavioral risk factor assessment included frequency of
intercourse, and use of contraception. Approximately
81.6% reported having sexual intercourse at least a few
times per week, while 3.1% reported having intercourse a
few times per month. Use of contraception was evaluated
on the basis of a participant utilizing some form of con-
traception at least once. About half (51.5 %) of the partic-
ipants had never used any form of contraception and half
(48.5%) had utilized contraception. The majority of par-
ticipants never used condoms (71.2%) with a stable part-
ner and a substantial fraction (27.3%) sporadically
utilized condoms.
Socio-demographic characteristics in reference to HPV 
prevalence
The overall prevalence of HPV among study participants
was 65.4% and 45% for HIV. HPV prevalence in HIV pos-
itive participants was 80%, and 55.0% in HIV negative
participants (Table 1). The prevalence of HPV HR and LR
and infections was calculated in relation to the popula-
tion characteristics. Multiple infections were observed in
11.4% of the study participants, 7.1% of those observed
in HIV positive patients and 4.3% in HIV negative
patients. HR and LR HPV infection prevalence for all par-
ticipants was 50% and 22.9%, respectively (Table 1). HIV
positive patients had a frequency of HR HPV infection at
70.0% and LR HPV infection frequency of 26.7%, whereas
HIV negative patients were found to have an infection fre-
quency of 35% for HR and 20% for LR HPVs.
HPV genotype distribution
The incidence of both HR and LR genotypes was deter-
mined in both HIV positive and negative patient samples
to determine if HIV status influences the distribution of
HPV genotypes (Table 2). We discovered an obvious
increase in the frequency of HR HPVs, specifically HPV18,
in HIV positive versus HIV negative patients. However, We
found that the incidence of low-risk HPVs was unaffected
by HIV status.
Figure 1a shows the distribution of HPV risk types in ref-
erence to worldwide data and Zambia. Worldwide HPV
data was adapted from G.M. Clifford and C. M. Wheeler
[4,5]. The two studies were utilized to assess worldwide
distribution of HPV types. HPV type prevalence data from
the US study was normalized to regional type prevalence
data collected in the Clifford et al. worldwide HPV study
[See Additional file 1]. Normalization of worldwide data
produced HR/LR distributions to be 64% and 36% respec-
tively. Similarly, the observed Zambian distribution for
HR HPVs was 68.6% and 31.4% for LR HPVs. The correla-
tion of HIV status with HPV risk type distribution among
the Zambian cohort is represented in Figure 1b. HIV neg-
ative participants were found to have risk-type distribu-
tions similar to the larger worldwide population. The HPV
distribution for HIV negative participants was 63.6% HR
to 36.4% LR. HIV positive participants displayed a signif-
icantly higher distribution of HR HPVs than that found in
the HIV negative group or in the worldwide data. The HR
HPV distribution was shown to be 72.4% and LR HPV was
present in 27.6% of HPV infections for the HIV positive
group of Zambian patients.
Genotype frequencies from the worldwide HPV approxi-
mation and Zambia are shown in Figure 2. Worldwide,
HPV16 has been shown to the predominating HPV geno-
type with a 14% frequency. Other prominent HR geno-
types worldwide include HPV18, 31, 56, and 58; all ofBMC Infectious Diseases 2007, 7:77 http://www.biomedcentral.com/1471-2334/7/77
Page 5 of 10
(page number not for citation purposes)
Table 1: Socio-demographics and diseases in relation to HPV prevalence.
Prevalence of HPV, %
Characteristic Number (%) Any HPV P value HR HPV P value LR HPV P Value
Total 70(100) 65.4 50.0 22.9
HIV Status
HIV+ 30(45) 80.0 0.05 70.0 0.05 26.7 0.2
HIV- 40(55) 55.0 35.0 20.0
Age in years
15–22 30(42) 45.0 0.001 33.3 0.001 13.3 0.025
23–30 27(45) 64.0 59.3 33.3
31–38 8(12) 78.0 75.0 12.5
Tribal Identity
Bemba 25(37.9) 60.0 0.001 48.0 0.001 20.0 0.001
Kaonde 2(3.0) 50.0 50.0 0.0
Lozi 4(6.1) 100.0 75.0 50.0
Luvale 1(1.5) 0.0 0.0 0.0
Nyanja 24(36.4) 45.8 37.5 16.7
Tonga 10(15.1) 80.0 70.0 30.0
Marital Status
Married 57(90.5) 63.2 0.001 50.9 0.001 24.6 1.0
Single 4(6.3) 50.0 50.0 0.0
Live-in partner 2(3.2) 50.0 50.0 0.0
Education Status
1–7 years 35(54.7) 68.6 0.2 57.1 0.2 22.9 0.001
8–12 years 25(39.1) 56.0 44.0 20.0
>12 years 4(6.2) 25.0 25.0 25.0
Age of Sexual Debut
≤ 15 19(28.8) 57.9 1.0 42.1 1.0 21.1 1
16–17 18(27.3) 61.1 44.4 27.8
18–19 13(19.7) 76.9 69.2 23.1
≥ 20 16(24.2) 43.8 43.8 12.5
Frequency Of Sex
Daily 1(1.5) 100.0 0.001 100.0 0.001 0.0 0.001
Once per week 6(9.2) 83.3 66.7 33.3
Few per week 53(81.6) 69.8 58.5 24.5
Few per month 2(3.1) 50.0 0.0 50.0
Few per year 3(4.6) 33.3 33.3 0.0
No Contraceptive ever used
Yes 34(51.5) 58.8 1.0 47.1 1.0 17.6 1
No 32(48.5) 59.4 50.0 25.0
Use of Condom with Stable Partner
Always 1(1.5) 100.0 0.001 0.0 0.001 100.0 0.001
Frequently 4(6.1) 50.0 25.0 75.0
Occasionally 14(21.2) 57.1 50.0 21.4
Never 47(71.2) 59.6 51.1 14.9
Presence of Traditional Scarification
Present 17(25.8) 70.6 0.001 64.7 0.001 17.6 0.1
Absent 49(74.2) 53.1 40.8 22.4
Hematinics
Yes 42(62.7) 52.4 0.025 42.9 0.025 19.0 0.1
No 25(37.3) 68.0 56.0 24.0
History of Antibiotic Use
Yes 36(55.4) 61.1 1.0 50.0 1.0 22.2 1
No 29(48.5) 55.2 70.0 20.7
The total number of various characteristics are indicated in response to the study questions (Numbers (%)). The prevalence of HPV (Any HPV) 
varies significantly across categories (P < 0.05, χ2 test). The prevalence of low-risk HPV (LR HPV) varied significantly across categories (P < 0.05, χ2 
test). The prevalence of high-risk HPV (HR HPV) also varied significantly across categories (P < 0.05, χ2 test).BMC Infectious Diseases 2007, 7:77 http://www.biomedcentral.com/1471-2334/7/77
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which are present at a frequency of 5% worldwide. The
Zambian cohort was found to have two predominating
HR genotypes, HPV16 frequency 21.6% and HPV18 fre-
quency 21.6%. HPV18 frequency was approximately four-
fold higher in the Zambian cohort than that reported
worldwide.
Frequency of HPV genotypes was also assessed according
to HIV status (Figure 3b). Genotype frequencies associ-
ated with HIV negative status was comparable to genotype
frequencies observed worldwide, in that HPV16 was the
predominating HPV genotype present. HIV positive status
was associated with a nine-fold higher frequency of HPV
and a moderate decline in HPV16 frequency compared to
the HIV negative group. Age-related affects do not explain
these differences since both HIV positive and negative
patients had the same mean and median ages (22 years
old). The nine-fold increase in HPV18 frequency among
HIV positive participants accounted, almost solely, as the
primary factor for the higher prevalence of HR HPV types
in HIV positive participants. This difference was signifi-
cant with a Chi-squared of 6.38, at a p-value of 0.025.
Discussion
In this study we investigated the distribution of HPVs in a
population of Zambians who were patients of the UTH in
Lusaka. The average rate of HIV infection in Zambia is
approximately 25.4% in urban areas and 11.5% in rural
areas [27]. However, in our study group, 45% of patients
were HIV positive. It is reasonable that this high rate of
HIV infection indicates that this population is at a higher
relative risk for sexually transmitted disease. Patients who
Table 2: The frequency of HPV genotypes in HIV positive and negative patients.
HPV Genotype HIV+ Group HIV- Group Total
HPV Frequency Percent HPV Frequency Percent HPV Frequency Percent
High Risk
16 41 3 . 873 1 . 8 1 1 2 1 . 6
18 10 34.5 1 4.5 11 21.6
58 1 3.4 1 4.5 2 3.9
35 1 3.4 1 4.5 2 3.9
45 1 3 . 4 001 2 . 0
51 1 3 . 4 001 2 . 0
50 1 3.4 1 4.5 2 3.9
83 1 3 . 4 001 2 . 0
67 1 3 . 4 001 2 . 0
33 002 9 . 1 2 3 . 9
8 001 4 . 5 1 2 . 0
Total 21 14 35
Low Risk
6 2 6.9 2 9.1 4 7.8
3 1 3.4 1 4.5 2 3.9
54 1 3.4 1 4.5 2 3.9
43 2 6.9 1 4.5 3 5.9
91 1 3 . 4 001 2 . 0
45 1 3 . 4 001 2 . 0
62 001 4 . 5 1 2 . 0
74 001 4 . 5 1 2 . 0
81 001 4 . 5 1 2 . 0
Total 8 8 16
HPV Negative 6 18 24
HPV Positive 29 22 54
Number of 
Samples
35 40 75
The incidence of each HPV genotype was determined and the percent total representation of each was calculated. Genotypes were recorded on a 
per incident basis since several patients had multiple HPVs. The data is represented graphically in figure 2.BMC Infectious Diseases 2007, 7:77 http://www.biomedcentral.com/1471-2334/7/77
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are admitted to UTH are aware that they are having health
problems and often this is indirectly related to their HIV
status.
There appeared to be a number of socio-demographic fac-
tors that were predictive of HPV status (Table 1). Older
patients, between the age of 23–30 or 31–38, were at least
two-fold more likely to be infected with an HR HPV than
patients who were 15–22 years old. Similarly, patients
between the age of 23–30 were two-fold more likely to be
infected with an LR HPV than the 15–22 year old group.
Most of our patients (90.5%) were married.
There appeared to be a moderately greater likelihood that
a given patient was HR HPV infected if they had a lower
education level (1–7 years) versus 8–12 years. The age of
sexual debut was reliably predictive of HR HPV infection;
patients who reported their first sexual experience
between 18–19 years of age were most likely to be infected
with an HR HPV. However, age of sexual debut appeared
not to be significantly predictive of LR HPV infection.
We compared the ratio of HR to LR HPVs in Zambia to the
worldwide distribution [4] (Figure 1a). We found that the
worldwide distribution of HR (64%) and LR HPVs (36%)
was very similar to that in Zambia; HR (69%) and LR
HPVs (31%) [5]. This suggests that the Zambia popula-
tion is not unusual with reference to the worldwide distri-
bution. However, There was a significant effect of HIV on
the percentage of HR HPV infection detected (Figure 1b).
In HIV positive individuals the HR to LR ratio was 78% to
22% versus 63.6% to 36.4% in HIV negative individuals.
This effect has been observed by other studies [28] and it
is clear that the effect of HIV on the frequency of HPV
infection is likely to be related to HIV-dependent immune
suppression [17,29,30].
We identified HPV DNAs in vaginal lavage samples by
amplification using GP5+/GP6+ and CPI/CPII primer
sets. We discovered that HPV16 and HPV18 each were
present in 21.6% of Zambian samples (Figure 2). The
aggregate worldwide rates of HPV16 and 18 are 14% and
5% respectively. Thus, HPV18 is present in this Zambian
population at about four-fold higher than the average
world rate [4]. The approximate rates of HPV16 and
HPV18 in the US are 7.5% and 2.3%, respectively [5]. In
Zambian patients, this corresponds to about a three-fold
and nine-fold greater incidence of a HPV16 and HPV18,
respectively. This finding, potentially, explains the high
rates of cervical cancer in Zambia and other sub-Saharan
countries [23,31-34]. As other laboratories have reported,
we observed a significant increase in HPV incidence as a
function of positive HIV status [13,32,33,35,36]. Specifi-
The frequency of HPV genotypes in Zambia as compared to  the worldwide HPV distribution Figure 2
The frequency of HPV genotypes in Zambia as compared to 
the worldwide HPV distribution. The worldwide HPV data 
was adapted from Clifford et al. (2005) and Peyton et al. 
(2001) [4] [5]. Both HPV16 and HPV18 were present at 
21.6% compared to 14% and 5%, for HPV16 and HPV18, 
respectively.
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a. HPV infections are graphed by risk type comparing world-
wide and Zambian HPV distributions. The worldwide HPV 
distribution data was adapted from Clifford et al. (2005) and 
Peyton etal. (2001) [4] [5] [See Additional file 1]. High-risk 
(HR; blue) and Low-risk (LR; red) HPV distributions among 
Zambian and worldwide populations. 1b. HPV infections by 
risk type in relation to HIV status. High-risk (HR; blue) and 
Low-risk (LR; red) HPV distributions are graphed as a func-
tion of HIV status for Zambian study participants. The distri-
bution of HR and LR HPVs is displayed as the percent of HPV 
infections in participants. Positive HIV status is associated 
with a higher prevalence of HR HPV infections.
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cally, we observed that incidence of HPV was 55% in HIV
negative patients whereas, the HPV incidence in HIV pos-
itive individuals was 80% (p = 0.05) (Figure 3a). This
probably represents increased replication efficiency of
viruses in patients with compromised immune systems.
Although, intuitively, it would seem reasonable that all
HPVs should increase in frequency in HIV positive indi-
viduals, we observed a non-random increase in the inci-
dence of certain HPV genotypes. We found a nine-fold
increase in the incidence of HPV18 in HIV positive versus
HIV negative patients (Figure 3b). Despite these differ-
ences in HPV distribution, all of the women in our study
had normal pap smears, suggesting that HIV status alters
HPV infection at levels of disease that are clinically unap-
parent. Other studies have witnessed this effect for HPV18
in the presence of HIV infection, though no studies have
provided explanations. Studies in Zimbabwe by Baay and
colleagues observed a three-fold increase in HPV18 inci-
dence in HIV positive individuals [13,15], similar to our
observations. The depletion of memory T cells by HIV
could be responsible for the genotype specific differences
due to loss of critical portions of the T cell receptor reper-
toire.
A recent study by Parham et al. [37] in Zambian patients
at the UTH found a strong correlation between low CD4
counts (<200 cells/µl) and the odds of finding severe cyto-
logical abnormalities. In contrast to our studies, all of the
patients in their study were HIV positive and the rates of
high-grade lesions was also high. While in our study, we
observed 69% of the patients infected with HR HPVs, the
Parham study reported 85%, a result which is likely to be
consistent with risk-level in HIV positive patients. The
presence of cytological abnormalities in HIV positive
patients is, not surprisingly, predictive of patients being
positive for an HR HPV and vice versa [37].
The comprehensive study by Clifford et al. [4] compared
HPV genotype distributions in Nigeria, India, Vietnam,
Thailand, Korea, Colombia, Argentina, Chile, the Nether-
lands, Italy, and Spain. The patients in this study were not
tested for HIV. However, the authors speculated that
regional differences in the distribution of HPVs other than
HPV16 could be partly explained endemic HIV, particu-
larly in Nigeria and India. Out of 3230 patients with no
cytological abnormalities, the prevalence for any HPV was
36.3% and 11.9% for multiple HPV types. The six most
common high-risk HPV types were 16 (4.5%), 58 (3.6%),
18 (3.1%), 52 (2.8%), 31 (2.0%) and 33 (2.0%) [4]. In
our Zambian study population, we discovered pro-
nounced differences in HPV distribution from the study of
Clifford et al. [4]. For example, the most common HPV
types in our study were 16 (21.6%), 18 (21.6%), 6
(7.8%), 43 (5.9%), 58 (3.9%), 35 (3.9%), 50 (3.9%), 54
(3.9%), 33 (3.9%) and 3 (3.9%). Furthermore, HPV type
31 was not recovered in our patient group. Thus, we con-
clude that the distribution of HPVs in this population dif-
fers significantly from the worldwide and US averages
[4,5] and that this is influenced by HIV status. The study
by Clifford et al (2006) found that HIV-positive women
with HSIL were significantly more likely to be infected
with HPV types 11, 18, 33, 51, 52, 53, 58 and 61, and with
multiple HPV types [38]. These results are consistent with
our observations. Our study made use of standard PCR
methods, similar to those of Peyton et al. (2000) and Clif-
ford et al. (2005) [4,5]. In our patient group, we had an
HIV positive rate of 45%. The most dramatic difference
attributable to HIV that we noted was a statistically signif-
icant increase in HPV18 in HIV positive patients.
a The incidence of HPV was calculated as a function of HIV  status Figure 3
a The incidence of HPV was calculated as a function of HIV 
status. The data was normalized as percent incidence to 
assesses possible effects or associations of HIV status with 
HPV infection. 3b. The prevalence of HPV genotypes present 
in patients was assessed for both HIV positive (black) and 
negative patients (gray). The graph displays HPV genotypes 
on the x-axis and the frequency of each genotype on the y-
axis. HR indicates high-risk strains and LR, represents the 
low-risk strains.
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Conclusion
In conclusion, our studies suggest a very active interaction
between HIV and HPV that is likely to de-repress the rep-
lication of HR HPVs (HPV18; figure 3b). The high rates of
HPV16 and 18 in Zambia are several-fold higher than
those found in the US and likely to be, at least partly, due
to the prevalence of HIV infection and the immunosup-
pressive effects of HIV. This also raises the question of
whether there is increased rate of transmission of particu-
lar HR HPVs in couples in which one or both of the part-
ners is HIV positive.
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